The Financial Times: Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

Scientists at UC say restoring a brain protein, not removing amyloid plaques, should be the target

The debate over a new drug to treat Alzheimer's is still going strong, with many experts rebutting the science behind its recent FDA approval. One of the most vocal voices objecting to the new drug is UC's Alberto Espay, MD.   

“The FDA approval will stimulate further investments into a hypothesis that should have long ago been falsified,” Espay told The Finanical Times. 

Espay and a team of researchers at UC and the  Karolinska Institute in Sweden back his position with their recent, and highly publicized study, pointing to a different target for the treatment of Alzheimer's disease. 

Read The Financial Times article, which has been reprinted in several international news outlets, includinh Kenya News.

Read more about Espay and the UC-led study.

Featured image at top of Alberto Espay, MD. Photo/Colleen Kelley/UC Creative + Brand

Impact Lives Here

The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.

Related Stories

1

Put down that beer; it's not a tanning lotion

July 1, 2024

The University of Cincinnati's Kelly Dobos joined WVXU's Cincinnati Edition to discuss what's fact and what's myth when it comes to sunscreen use, different kinds of sunscreen and a social media recommendation to use beer on your skin to help get a tan.

2

Cincinnati researchers want to know if MRIs can work better

June 28, 2024

WVXU and the Cincinnati Business Courier highlighted a new collaboration between the University of Cincinnati College of Medicine, UC Health GE HealthCare, JobsOhio, REDI Cincinnati and Cincinnati Children’s to create an MRI Research and Development Center of Excellence located on UC’s medical campus.

Debug Query for this